"Tuberculosis, Pulmonary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
MYCOBACTERIUM infections of the lung.
Descriptor ID |
D014397
|
MeSH Number(s) |
C01.252.410.040.552.846.899 C08.381.922 C08.730.939
|
Concept/Terms |
Tuberculosis, Pulmonary- Tuberculosis, Pulmonary
- Tuberculoses, Pulmonary
- Pulmonary Tuberculoses
- Pulmonary Tuberculosis
- Pulmonary Consumption
- Consumption, Pulmonary
- Consumptions, Pulmonary
- Pulmonary Consumptions
- Pulmonary Phthisis
- Phthises, Pulmonary
- Phthisis, Pulmonary
- Pulmonary Phthises
|
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Pulmonary".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Pulmonary".
This graph shows the total number of publications written about "Tuberculosis, Pulmonary" by people in this website by year, and whether "Tuberculosis, Pulmonary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 1 | 0 | 1 |
1998 | 4 | 0 | 4 |
1999 | 2 | 1 | 3 |
2000 | 1 | 1 | 2 |
2001 | 4 | 1 | 5 |
2002 | 2 | 2 | 4 |
2003 | 2 | 0 | 2 |
2004 | 1 | 0 | 1 |
2005 | 1 | 1 | 2 |
2006 | 2 | 0 | 2 |
2007 | 7 | 2 | 9 |
2008 | 1 | 2 | 3 |
2009 | 1 | 0 | 1 |
2010 | 4 | 0 | 4 |
2011 | 6 | 1 | 7 |
2012 | 9 | 1 | 10 |
2013 | 7 | 0 | 7 |
2014 | 7 | 0 | 7 |
2015 | 11 | 1 | 12 |
2016 | 15 | 1 | 16 |
2017 | 10 | 1 | 11 |
2018 | 8 | 3 | 11 |
2019 | 13 | 0 | 13 |
2020 | 11 | 1 | 12 |
2021 | 9 | 0 | 9 |
2022 | 4 | 0 | 4 |
2023 | 10 | 0 | 10 |
2024 | 4 | 2 | 6 |
2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tuberculosis, Pulmonary" by people in Profiles.
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
-
Levofloxacin Preventive Treatment in Children Exposed to MDR Tuberculosis. N Engl J Med. 2024 Dec 19; 391(24):2315-2326.
-
The effect of previous SARS-CoV-2 infection on systemic immune responses in individuals with tuberculosis. Front Immunol. 2024; 15:1357360.
-
Simultaneous alleviation of verification and reference standard biases in a community-based tuberculosis screening study using Bayesian latent class analysis. PLoS One. 2024; 19(6):e0305126.
-
Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance. J Mol Diagn. 2024 Aug; 26(8):708-718.
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
-
Xpert MTB/RIF Ultra versus mycobacterial growth indicator tube liquid culture for detection of Mycobacterium tuberculosis in symptomatic adults: a diagnostic accuracy study. Lancet Microbe. 2024 Jun; 5(6):e520-e528.
-
The performance of tongue swabs for detection of pulmonary tuberculosis. Front Cell Infect Microbiol. 2023; 13:1186191.
-
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study. Clin Infect Dis. 2023 08 14; 77(3):453-459.
-
Introducing a secondary segmentation to construct a radiomics model for pulmonary tuberculosis cavities. Radiol Med. 2023 Sep; 128(9):1093-1102.